| Sheryl R Simon, MD | |
|
2602 Wilmington Rd, Suite 101, New Castle, PA 16105-1537 | |
| (724) 658-7300 | |
| (724) 658-8414 |
| Full Name | Sheryl R Simon |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 2602 Wilmington Rd, New Castle, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063486603 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD034047E (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sheryl R Simon, MD 2602 Wilmington Rd, Suite 101, New Castle, PA 16105-1537 Ph: (724) 658-7300 | Sheryl R Simon, MD 2602 Wilmington Rd, Suite 101, New Castle, PA 16105-1537 Ph: (724) 658-7300 |
News Archive
Authentidate Holding Corp. (Nasdaq: ADAT), a worldwide provider of secure Health Information Exchange and workflow management services, today announced that LifeCare Solutions, Inc., a leading Western U.S. provider of home healthcare services and medical equipment, selected Authentidate's Inscrybe(TM) Healthcare web-based service to simplify completion of healthcare documentation with physicians.
Supported by thousands of years of use, a new wave of polymolecular botanical drugs (PBDs), backed by strong biomedical research and clinical trials, are growing in acceptance as a viable new drug category for the treatment and prevention of a wide spectrum of diseases from cancer to obesity.
Anchor Therapeutics today announced an initial closing of $10 million in a Series B financing. The investment is being led by current investors TVM Capital, HealthCare Ventures and the Novartis Option Fund. The company is in continuing discussions with additional investors interested in joining the Series B. Anchor Therapeutics is focused on developing peptide drug candidates, called pepducins, that modulate G protein coupled receptors (GPCRs), particularly those historically difficult to target using standard pharmaceutical approaches.
A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.
Instead of responding to natural disasters after they happen, aid should be dedicated to helping countries prepare for future disasters, John Holmes, the U.N.'s emergency relief coordinator, said Friday, Reuters reports.
› Verified 5 days ago
Ankur Panchal, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1211 Wilmington Ave, Jameson Hospital, New Castle, PA 16105 Phone: 724-656-4264 | |
Dr. Silvia E Coleman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 125 Enclave Dr, New Castle, PA 16105 Phone: 724-658-6656 Fax: 724-658-6542 | |
Ramesh Kaul, MD, FCCP, MS Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2602 Wilmington Rd, Suite 102, New Castle, PA 16105 Phone: 724-657-5285 Fax: 724-657-6714 | |
Dr. Sandra Milena Pinzon, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2004 W State St, New Castle, PA 16101 Phone: 724-656-4037 | |
Dr. Mohamed K Tejpar, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2602 Wilmington Rd, Suite 208, New Castle, PA 16105 Phone: 724-658-6583 Fax: 724-658-6081 | |
Dr. Kamal Wadhwa, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2602 Wilmington Rd, Suite 200, New Castle, PA 16105 Phone: 724-657-3204 Fax: 724-652-7144 |